1] Key laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Surgery [2].
Sci Rep. 2013 Oct 21;3:2992. doi: 10.1038/srep02992.
A preclinical trial identified 4 of 20 (20%) gastric cancer (GC) patient-derived xenografts responded to cetuximab. Genome-wide profiling and additional investigations revealed that high EGFR mRNA expression and immunohistochemistry score (3+) are associated with tumor growth inhibition. Furthermore, EGFR amplification were observed in 2/4 (50%) responders with average copy number 5.8 and >15 respectively. Our data suggest that a GC subtype with EGFR amplification and overexpression benefit from cetuximab treatment.
一项临床前试验发现，20 例胃癌（GC）患者衍生异种移植物中有 4 例（20%）对西妥昔单抗有反应。全基因组分析和进一步的研究表明，高 EGFR mRNA 表达和免疫组织化学评分（3+）与肿瘤生长抑制相关。此外，在 2/4（50%）的应答者中观察到 EGFR 扩增，平均拷贝数分别为 5.8 和 >15。我们的数据表明，具有 EGFR 扩增和过表达的 GC 亚型受益于西妥昔单抗治疗。
